These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. N-acetylation phenotyping with sulphadimidine in a Turkish population. Bozkurt A; Basci NE; Kalan S; Tuncer M; Kayaalp SO Eur J Clin Pharmacol; 1990; 38(1):53-6. PubMed ID: 2328748 [TBL] [Abstract][Full Text] [Related]
3. Effect of concomitant isoniazid administration on determination of acetylator phenotype by sulphadimidine. Zysset T; Peretti E Eur J Clin Pharmacol; 1986; 30(4):463-6. PubMed ID: 3743623 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the sulphadimidine acetylator phenotyping test in patients with reduced renal function. Hall S Acta Med Scand; 1981; 209(6):505-7. PubMed ID: 7257867 [TBL] [Abstract][Full Text] [Related]
5. N-acetylation in healthy and diseased children. Hadasová E; Brysová V; Kadlcáková E Eur J Clin Pharmacol; 1990; 39(1):43-7. PubMed ID: 2276387 [TBL] [Abstract][Full Text] [Related]
6. Orofacial clefts and spina bifida: N-acetyltransferase phenotype, maternal smoking, and medication use. van Rooij IA; Groenen PM; van Drongelen M; Te Morsche RH; Peters WH; Steegers-Theunissen RP Teratology; 2002 Nov; 66(5):260-6. PubMed ID: 12397635 [TBL] [Abstract][Full Text] [Related]
7. Sulphamethoxazole acetylation in fast and slow acetylators. Bozkurt A; Basci NE; Isimer A; Tuncer M; Erdal R; Kayaalp SO Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):164-6. PubMed ID: 2338369 [TBL] [Abstract][Full Text] [Related]
8. Possible optimization of sulphadimidine dosage for acetylator phenotyping. Hombhanje F Jpn J Pharmacol; 1991 Aug; 56(4):531-4. PubMed ID: 1744992 [TBL] [Abstract][Full Text] [Related]
9. Drug acetylation and expression of lupus erythematosus. Marsden JR; Mason GG; Coburn PR; Rawlins MD; Shuster S Eur J Clin Pharmacol; 1985; 28(4):387-90. PubMed ID: 4029245 [TBL] [Abstract][Full Text] [Related]
10. Acetylator phenotyping with sulphadimidine in patients receiving isoniazid. Ylitalo P; Auterinen L; Marttinen A; Koivula T Int J Clin Pharmacol Res; 1984; 4(2):141-4. PubMed ID: 6469440 [TBL] [Abstract][Full Text] [Related]
11. Genetically determined variability in acetylation and oxidation. Therapeutic implications. Clark DW Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977 [TBL] [Abstract][Full Text] [Related]
14. Relationship between acetylator phenotype and intensity of the hypoglycaemic effect of a suplhonamide preparation in children with insulin-dependent diabetes. Hadasová E; Brysová V; Utĕsený J; Macků M Bratisl Lek Listy; 1991 Dec; 92(12):609-14. PubMed ID: 1806177 [TBL] [Abstract][Full Text] [Related]
15. Acetylator phenotype and the antihypertensive response to hydralazine. Jounela AJ; Pasanen M; Mattila MJ Acta Med Scand; 1975 Apr; 197(4):303-6. PubMed ID: 1136859 [TBL] [Abstract][Full Text] [Related]
16. Comparison between serum and urinary sulphadimidine acetylation as predictors of isoniazid acetylator status in patients with pulmonary tuberculosis. Singh SP; Pande JN; Khilnani GC; Kailash S Indian J Chest Dis Allied Sci; 1996; 38(1):5-11. PubMed ID: 16892742 [TBL] [Abstract][Full Text] [Related]
17. The association of the slow acetylator phenotype with bladder cancer. Evans DA; Eze LC; Whibley EJ J Med Genet; 1983 Oct; 20(5):330-3. PubMed ID: 6644762 [TBL] [Abstract][Full Text] [Related]
18. Comparison between serum isonicotinic acid hydrazide (INH) levels and urinary sulfadimidine (sulfamethazine) acetylation as predictors of INH acetylator status. Seth V; Seth SD; Beotra A; Singh U Dev Pharmacol Ther; 1988; 11(1):32-6. PubMed ID: 3383719 [TBL] [Abstract][Full Text] [Related]
19. Association of microalbuminuria with slow acetylator phenotype in type 1 diabetes mellitus. Madácsy L; Szórády I; Sánta A; Barkai L; Vámosi I Child Nephrol Urol; 1992; 12(4):192-6. PubMed ID: 1473091 [TBL] [Abstract][Full Text] [Related]